Influence of glycemic control on the development of diabetic cardiovascular and kidney disease

Cardiology Clinics

Volumn 28, Issue 3, 2010, Pages 497-516

  Saha, Sandeep A ^a,b   Tuttle, Katherine R ^a,b  

^a SACRED HEART MEDICAL CENTER   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

CKD; Heart disease; Incretin; Insulin; Metformin; PKC inhibitors; Sulfonylureas; Thiazolidinediones

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ADVANCED GLYCATION END PRODUCT INHIBITOR; ANTIDIABETIC AGENT; BIGUANIDE DERIVATIVE; CHLORPROPAMIDE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLIPIZIDE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; HEMOGLOBIN A1C; INSULIN; LIRAGLUTIDE; MEGLITINIDE; METFORMIN; NATEGLINIDE; PHENFORMIN; PIOGLITAZONE; PLACEBO; PROTEIN KINASE C INHIBITOR; REPAGLINIDE; ROSIGLITAZONE; SITAGLIPTIN; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SULFONYLUREA DERIVATIVE; TOLBUTAMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG FATALITY; EVIDENCE BASED MEDICINE; GASTROINTESTINAL SYMPTOM; GLYCEMIC CONTROL; HEART FAILURE; HEART INFARCTION; HUMAN; HYPOGLYCEMIA; KIDNEY DISEASE; LACTIC ACIDOSIS; MICROANGIOPATHY; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL EDEMA; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; UNSPECIFIED SIDE EFFECT; VASCULAR DISEASE; WEIGHT GAIN; CARDIOVASCULAR DISEASES; COMPLICATION; CONTRAINDICATIONS; DIABETIC NEPHROPATHIES; MULTIMODALITY CANCER THERAPY;

ACARBOSE; BIGUANIDES; CARDIOVASCULAR DISEASES; COMBINED MODALITY THERAPY; DIABETES MELLITUS; DIABETIC NEPHROPATHIES; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; SULFONYLUREA COMPOUNDS; THIAZOLIDINEDIONES;

EID: 77954504624     PISSN: 07338651     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccl.2010.04.008     Document Type: Review

References (137)

1. World Health Organization Fact sheet no. 312: what is diabetes? Available at:, Accessed October 16, 2009. http://www.who.int/mediacentre/factsheets/fs312/en/.
2. Wild S., Roglic G., Green A., et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004, 27(5):1047-1053.
3. National Kidney Foundation - Kidney Disease Outcomes Quality Initiative (NKF-KDOQI) Clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis 2007, 49:S1-179.
4. American Heart Association Heart disease and stroke statistics-2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2008, 117(4):e25-146.
5. Nathan D.M., Zinman B., Cleary P.A., et al. Modern-day clinical course of type 1 diabetes mellitus after 30 years' duration: the diabetes control and complications trial/epidemiology of diabetes interventions and complications and Pittsburgh epidemiology of diabetes complications experience (1983-2005). Arch Intern Med 2009, 169(14):1307-1316. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Research Group.
6. Holman R.R., Paul S.K., Bethel M.A., et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008, 359(15):1577-1589.
7. U.S. Renal Data System, USRDS 2009 Annual data report: Atlas of chronic kidney disease and end-stage renal disease in the United States 2009, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda (MD), Available at:, Accessed January 11, 2010. http://www.usrds.org/2009/view/v1_00a_intro.asp.
8. Adler A., Stevens R., Manley S., et al. Development and progression of nephropathy in type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 2003, 63:225-232.
9. International Diabetes Federation The human, social and economic impact of diabetes Available at:, Accessed October 16, 2009. http://www.idf.org/home/index.cfm?node=41./.
10. Wiernsperger N.F., Bailey C.J. The antihyperglycaemic effect of metformin: therapeutic and cellular mechanisms. Drugs 1999, 58(Suppl 1):31-39.
11. University Group Diabetes Program. A study of the effects of hypoglycemic agents on vascular complications on patients with adult-onset diabetes: V. evaluation of phenformin therapy. Diabetes 1975, 24(Suppl 1):65-184.
12. Stang M., Wysowski D.K., Butler-Jones D. Incidence of lactic acidosis in metformin users. Diabetes Care 1999, 22:925-927.
13. Davidson M.B., Peters A.L. An overview of metformin in the treatment of type 2 diabetes mellitus. Am J Med 1997, 102:99-110.
14. DeFronzo R. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med 1999, 131:281-303.
15. National Kidney Foundation KDOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification Available at:, Accessed January 11, 2010. http://www.kidney.org/Professionals/Kdoqi/guidelines_ckd/toc.htm.
16. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998, 352:854-865. [erratum in: Lancet 1998;352:1558].
17. Inzucchi S.E. Metformin for heart failure-innocent until proven guilty. Diabetes Care 2005, 28:2585-2587.
18. Misbin R.I., Green L., Stadel B.V., et al. Lactic acidosis in patients with diabetes treated with metformin. N Engl J Med 1998, 338:265-266.
19. Rachmani R., Slavachevski I., Levi Z., et al. Metformin in patients with type 2 diabetes mellitus: reconsideration of traditional contraindications. Eur J Intern Med 2002, 13:428-433.
20. Eurich D.T., Majumdar S.R., McAlister F.A., et al. Improved clinical outcomes associated with metformin in patients with diabetes and heart failure. Diabetes Care 2005, 28:2345-2351.
21. Inzucchi S.E., Masoudi F.A., Wang Y., et al. Insulin-sensitizing antihyperglycemic drugs and mortality after acute myocardial infarction: insights from the National Heart Care Project. Diabetes Care 2005, 28:1680-1689.
22. Cryer D.R., Nicholas S.P., Henry D.H., et al. Comparative outcomes study of metformin intervention versus conventional approach-the COSMIC Approach Study. Diabetes Care 2005, 28:539-543.
23. Eurich D.T. Metformin treatment in diabetes and heart failure: when academic equipoise meets clinical reality. Trials 2009, 10:12.
24. Masoudi F.A., Wang Y., Inzucchi S.E., et al. Metformin and thiazolidinedione use in Medicare patients with heart failure. JAMA 2003, 290:81-85.
25. MicroMedex. DrugPoint Summary-Metformin hydrochloride-dosing and indications. Available at: Accessed November 9, 2009. http://www.micromedex.com/products/drugdex/.
26. Meinert C.L., Knatterud G.L., Prout T.E., et al. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results. Diabetes 1970, 19(Suppl):789-830.
27. Murry C.E., Jennings R.B., Reimer K.A. Preconditioning with ischemia: a delay in lethal injury in ischemic myocardium. Circulation 1986, 24:1124-1126.
28. Chutkow W.A., Simon M.C., Le Beau M.M., et al. Cloning, tissue expression, and chromosomal localization of SUR2, the putative drug-binding subunit of cardiac, skeletal muscle, and vascular KATP channels. Diabetes 1996, 45:1439-1445.
29. Lawrence C.L., Proks P., Rodrigo G.C., et al. Gliclazide produces a high-affinity block of KATP channels in mouse isolated pancreatic beta cells but not rat heart or arterial smooth muscle cells. Diabetologia 2001, 44:1019-1025.
30. Legtenberg R.J., Houston R.J., Oeseburg B., et al. Effects of sulfonylurea derivatives on ischemia-induced loss of function in the isolated rat heart. Eur J Pharmacol 2001, 419:85-92.
31. Dobrowski M., Wahl P., Holmes W.E., et al. Effect of repaglinide on cloned beta cell, cardiac and smooth muscle types of ATP-sensitive potassium channels. Diabetologia 2001, 44:747-756.
32. Lee T.M., Chou T.F. Impairment of myocardial protection in type 2 diabetic patients. J Clin Endocrinol Metab 2003, 88:531-537.
33. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998, 352:837-853. [erratum in: Lancet 1999;354:602].
34. Kahn S.E., Haffner S.M., Heise M.A., et al. ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006, 355:2427-2443. [erratum in: N Engl J Med 2007;356:1387-8].
35. Simpson S., Majumdar S., Tsuyuki R.T., et al. Dose-response relation between sulphonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort study. CMAJ 2006, 174(2):169-174.
36. Black C., Donnelly P., McIntyre L., et al. Meglitinide analogues for type 2 diabetes mellitus. Cochrane Database Syst Rev 2007, 2:CD00004654.
37. Johansen O.E., Birkeland K.I. Defining the role of repaglinide in the management of type 2 diabetes mellitus-a review. Am J Cardiovasc Drugs 2007, 7(5):319-335.
38. Hasslacher C. Safety and efficacy of repaglinide in type 2 diabetic patients with and without impaired renal function. Diabetes Care 2003, 26:886-891.
39. Schumacher S., Abbasi I., Weise D., et al. Single- and multiple-dose pharmacokinetics of repaglinide in patients with type 2 diabetes and renal impairment. Eur J Clin Pharmacol 2001, 57:147-152.
40. Willson T.M., Brown P.J., Sternbach D.D., et al. The PPARs: from orphan receptors to drug discovery. J Med Chem 2000, 43:527-550.
41. Spiegelman B.M. PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. Diabetes 1998, 47:507-514.
42. Sarafidis P.A., Bakris G.L. Protection of the kidney by thiazolidinediones: an assessment from bench to bedside. Kidney Int 2006, 70:1223-1233.
43. Dormandy J.A., Charbonnel B., Eckland D.J., et al. PROactive investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005, 366(9493):1279-1289.
44. Lebovitz H.E., Dole J.F., Patwardhan R., et al. Rosiglitazone monotherapy is effective in patients with type 2 diabetes. J Clin Endocrinol Metab 2001, 86:280-288.
45. Bakris G., Viberti G., Weston W.M., et al. Rosiglitazone reduces urinary albumin excretion in type 2 diabetes. J Hum Hypertens 2003, 17:7-12.
46. Aljabri K., Kozak S.E., Thompson D.M. Addition of pioglitazone or bedtime insulin to maximal doses of sulfonylurea and metformin in type 2 diabetes patients with poor glucose control: a prospective, randomized trial. Am J Med 2004, 116:230-235.
47. Hanefeld M., Brunetti P., Schernthaner G.H., et al. One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes. Diabetes Care 2004, 27:141-147.
48. Schernthaner G., Matthews D.R., Charbonnel B., et al. Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial. J Clin Endocrinol Metab 2004, 89:6068-6076.
49. Matthews D.R., Charbonnel B.H., Hanefeld M., et al. Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study. Diabetes Metab Res Rev 2005, 21:167-174.
50. Bakris G.L., Ruilope L.M., McMorn S.O., et al. Rosiglitazone reduces microalbuminuria and blood pressure independently of glycemia in type 2 diabetes patients with microalbuminuria. J Hypertens 2006, 24:2047-2055.
51. Ryan E.H., Han D.P., Ramsay R.C., et al. Diabetic macular edema associated with glitazone use. Retina 2006, 26:562-570.
52. ACTOS (pioglitazone hydrochloride) - full prescribing information and medication guide Available at:, Accessed January 11, 2010. http://www.actos.com/actospro/prescribinginfo.aspx.
53. Avandia (rosiglitazone maleate) prescribing information Available at:, Accessed January 11, 2010. http://us.gsk.com/products/assets/us_avandia.pdf.
54. Koshiyama H., Shimono D., Kuwamura N., et al. Rapid communication: inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 2001, 86:3452-3456.
55. Langenfeld M.R., Forst T., Hohberg C., et al. Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus: results from a controlled randomized study. Circulation 2005, 111:2525-2531.
56. Mazzone T., Meyer P.M., Feinstein S.B., et al. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA 2006, 296:2572-2581.
57. Takagi T., Yamamuro A., Tamita K., et al. Pioglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with type 2 diabetes mellitus: an intravascular ultrasound scanning study. Am Heart J 2003, 146:e5.
58. Riche D.M., Valderrama R., Henyan N.N. Thiazolidinediones and risk of repeat target vessel revascularization following percutaneous coronary intervention: a meta-analysis. Diabetes Care 2007, 30(2):384-388.
59. Gerstein H.C., Yusuf S., Bosch J., DREAM (Diabetes REduction Assessment with Ramipril and Rosiglitazone Medication) Trial Investigators, et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomized controlled trial. Lancet 2006, 368:1096-1105.
60. Nissen S.E., Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007, 356:2457-2471.
61. Lipscombe L.L., Gomes T., Lévesque L.E., et al. Thiazolidinediones and cardiovascular outcomes in older patients with diabetes. JAMA 2007, 298:2634-2643.
62. Singh S., Loke Y.K., Furberg C.D. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA 2007, 298:1189-1195.
63. Richter B., Bandeira-Echtler E., Bergerhoff K., et al. Rosiglitazone for type 2 diabetes mellitus. Cochrane Database Syst Rev 2007, 3. CD006063.
64. Mannucci E., Monami M., Di Bari M., et al. Cardiac safety profile of rosiglitazone. A comprehensive meta-analysis of randomized clinical trials. Int J Cardiol 2009, [Epub ahead of print].
65. Friedrich J.O., Beyene J., Adhikari N.K. Rosiglitazone: can meta-analysis accurately estimate excess cardiovascular risk given the available data? Re-analysis of randomized trials using various methodologic approaches. BMC Res Notes 2009, 2:5.
66. Lincoff A.M., Wolski K., Nicholls S.J., et al. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 2007, 298(10):1180-1188.
67. Mannucci E., Monami M., Lamanna C., et al. Pioglitazone and cardiovascular risk-a comprehensive meta-analysis of randomized clinical trials. Diabetes Obes Metab 2008, 10:1221-1238.
68. Nagajothi N., Adigopula S., Balamuthusamy S., et al. Pioglitazone and the risk of myocardial infarction and other major adverse cardiac events: a meta-analysis of randomized, controlled trials. Am J Ther 2008, 15:506-511.
69. Diamond G.A., Bax L., Kaul S. Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death. Ann Intern Med 2007, 147:578-581.
70. Fuster V., Farkouh M.E. Faster publication isn't always better. Nat Clin Pract Cardiovasc Med 2007, 4:345.
71. Mulrow C.D., Cornell J., Localio A.R. Rosiglitazone: a thunderstorm from scarce and fragile data. Ann Intern Med 2007, 147:585-587.
72. A desktop guide to type 2 diabetes mellitus: European Diabetes Policy Group 1999. Diabet Med 1999, 16:716-730.
73. Erdmann E., Dormandy J.A., Charbonnel B., et al. PROactive Investigators. The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study. J Am Coll Cardiol 2007, 49:1772-1780.
74. Pioglitazone protects DM patients against re-infarction (PPAR Study). (NCT00212004) Available at:, Accessed January 11, 2010. http://www.clinicaltrials.gov/ct2/show/NCT00212004?term=NCT00212004&rank=1.
75. Cobitz A., Zambanini A., Sowell M., et al. A retrospective evaluation of congestive heart failure and myocardial ischemia events in 14,237 patients with type 2 diabetes mellitus enrolled in 42 short-term, double-blind, randomized clinical studies with rosiglitazone. Pharmacoepidemiol Drug Saf 2008, 17:769-781.
76. Walker A.M., Koro C.E., Landon J. Coronary heart disease outcomes in patients receiving antidiabetic agents in the PharMetrics database 2000-2007. Pharmacoepidemiol Drug Saf 2008, 17(8):760-768.
77. Home P.D., Pocock S.J., Beck-Nielsen H., et al. RECORD Study Team. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 2009, 373:2125-2135.
78. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993, 329:977-986.
79. Nathan D.M., Cleary P.A., Backlund J.Y., et al. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005, 353:2643-2653.
80. Khaw K.T., Wareham N., Bingham S., et al. Association of hemoglobin A1c with cardiovascular disease and mortality in adults: the European prospective investigation into cancer in Norfolk. Ann Intern Med 2004, 141:413-420.
81. Dandona P., Chaudhuri A., Ghanim H., et al. Use of insulin to improve glycemic control in diabetes mellitus. Cardiovasc Drugs Ther 2008, 22:241-251.
82. Anselmino M., Ohrvik J., Malmberg K., et al. Euro Heart Survey Investigators. Glucose lowering treatment in patients with coronary artery disease is prognostically important not only in established but also in newly detected diabetes mellitus: a report from the Euro Heart Survey on Diabetes and the Heart. Eur Heart J 2008, 29:177-184.
83. Mellbin L.G., Malmberg K., Norhammar A., et al. DIGAMI 2 Investigators. The impact of glucose lowering treatment on long-term prognosis in patients with type 2 diabetes and myocardial infarction: a report from the DIGAMI 2 trial. Eur Heart J 2008, 29:166-176.
84. Mehta S.R., Yusuf S., Díaz R., et al. CREATE-ECLA Trial Group Investigators. Effect of glucose-insulin-potassium infusion on mortality in patients with acute ST-segment elevation myocardial infarction: the CREATE-ECLA randomized controlled trial. JAMA 2005, 293(4):437-446.
85. Díaz R., Goyal A., Mehta S.R., et al. Glucose-insulin-potassium therapy in patients with ST-segment elevation myocardial infarction. JAMA 2007, 298(20):2399-2405.
86. Chaudhuri A., Miller M., Nesto R., et al. Targeting glucose in acute myocardial infarction: has glucose, insulin, and potassium infusion missed the target. Diabetes Care 2007, 30:3026-3028.
87. Gerstein H.C., Miller M.E., Byington R.P., et al. Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008, 358:2545-2559.
88. Patel A., MacMahon S., Chalmers J., et al. ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008, 358:2560-2572.
89. Duckworth W., Abraira C., Moritz T., et al. VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009, 360:129-139.
90. Skyler J.S., Bergenstal R., Bonow R.O., et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA Diabetes Trials: a position statement of the American Diabetes Association and a Scientific Statement of the American College of Cardiology Foundation and the American Heart Association. J Am Coll Cardiol 2009, 53:298-304.
91. Dluhy R.G., McMahon G.T. Intensive glycemic control in the ACCORD and ADVANCE trials. N Engl J Med 2008, 358:2630-2633.
92. Cefalu W.T. Glycemic targets and cardiovascular disease. N Engl J Med 2008, 358:2633-2635.
93. Chiasson J.L., Josse R.G., Gomis R., et al. STOP-NIDDM Trial Research Group. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 2003, 290:486-494.
94. Chiasson J.L. Acarbose for the prevention of diabetes, hypertension, and cardiovascular disease in subjects with impaired glucose tolerance: the Study to Prevent Non-Insulin-Dependent Diabetes Mellitus (STOP-NIDDM) Trial. Endocr Pract 2006, 12(Suppl 1):25-30.
95. Steines W., Piehlmeier W., Schenkirsch G., et al. Effectiveness of a disease management programme for patients with type 2 diabetes mellitus and albuminuria in primary care - the PROSIT project (Proteinuria Screening and Intervention). Exp Clin Endocrinol Diabetes 2004, 112:88-94.
96. Gaede P., Lund-Anderson H., Parving H.H., et al. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008, 358:580-591.
97. Gaede P., Vedel P., Larsen N., et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003, 348:383-393.
98. Nauck M., Stöckmann F., Ebert R., et al. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 1986, 29:46-52.
99. Drucker D.J., Nauck M.A. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006, 368:1696-1705.
100. Klonoff D.C., Buse J.B., Nielsen L.L., et al. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin 2008, 24:275-286.
101. Bolen S., Feldman L., Vassy J., et al. Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Intern Med 2007, 147:386-399.
102. Amori R.E., Lau J., Pittas A.G. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA 2007, 298:194-206.
103. Sulistio M., Carothers C., Mangat M., et al. GLP-1 agonist-based therapies: an emerging new class of antidiabetic drug with potential cardioprotective effects. Curr Atheroscler Rep 2009, 11:93-99.
104. Sonne D.P., Engstrom T., Treiman M. Protective effects of GLP-1 analogues exendin-4 and GLP-1(9-36) amide against ischemia-reperfusion injury in rat heart. Regul Pept 2008, 146:243-249.
105. Noyan-Ashraf MH, Ban K, Sadi A, et al. The GLP-1R agonist liraglutide protects cardiomyocytes and improves survival and cardiac function after experimental murine infarction [abstract 190-OR]. Presented at the 68th scientific sessions of the American Diabetes Association. San Francisco (CA), June 6-10, 2008.
106. Kendall DM, Bhole D, Guan X, et al. Exenatide treatment for 82 weeks reduced C-reactive protein, HbA1c, and body weight in patients with type 2 diabetes mellitus. Presented at 42nd Congress of EASD. Copenhagen (Denmark), September 14-17, 2006.
107. Okerson T, Yan P, Stonehouse A, et al. Exenatide improved systolic blood pressure compared to insulin or placebo in patients with type 2 diabetes [abstract 877]. Presented at the 44th Annual meeting of the EASD. Rome (Italy), September 7-11, 2008.
108. Colagiuri S, Frid A, Zdravkovic M, et al. Liraglutide, a human GLP-1 analogue, reduces systolic blood pressure in subjects with type 2 diabetes in subjects with type 2 diabetes [abstract 899]. Presented at the 44th Annual meeting of the EASD. Rome (Italy), September 7-11, 2008.
109. Nathan D.M., Buse J.B., Davidson M.B., et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009, 32:193-203.
110. Roumen C., Blaak E.E., Corpeleijn E. Lifestyle intervention for prevention of diabetes: determinants of success for future implementation. Nutr Rev 2009, 67:132-146.
111. Flegal K.M., Graubard B.I., Williamson D.F., et al. Cause-specific excess deaths associated with underweight, overweight, and obesity. JAMA 2007, 298:2028-2037.
112. Snow V., Barry P., Fitterman N., et al. Clinical Efficacy Assessment Subcommittee of the American College of Physicians. Pharmacologic and surgical management of obesity in primary care: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2005, 142:525-531.
113. Knowler W.C., Barrett-Connor E., Fowler S.E., et al. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002, 346:393-403.
114. Diabetes Prevention Program Research Group 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet 2009, 374:1677-1686.
115. Morales E., Valero M.A., Leon M., et al. Beneficial effects of weight loss in overweight patients with chronic proteinuric nephropathies. Am J Kidney Dis 2003, 41:319-327.
116. Reid C.M., Dart A.M., Dewar E.M., et al. Interactions between the effects of exercise and weight loss on risk factors, cardiovascular haemodynamics and left ventricular structure in overweight subjects. J Hypertens 1994, 12(3):291-301.
117. Esposito K., Pontillo A., Di Palo C., et al. Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial. JAMA 2003, 289(14):1799-1804.
118. Skilton M.R., Sieveking D.P., Harmer J.A., et al. The effects of obesity and non-pharmacological weight loss on vascular and ventricular function and structure. Diabetes Obes Metab 2008, 10(10):874-884.
119. Goldberg Y., Boaz M., Matas Z., et al. Weight loss induced by nutritional and exercise intervention decreases arterial stiffness in obese subjects. Clin Nutr 2009, 28(1):21-25.
120. National Academy of Sciences, Institute of Medicine Dietary reference intakes for energy, carbohydrates, fiber, fat, fatty acids, cholesterol, protein and amino acids (Macronutrients) 2002, The National Academy Press, Washington, DC, Chapter 8.
121. Menne J., Meier M., Park J.K., et al. Inhibition of protein kinase C in diabetic nephropathy-where do we stand?. Nephrol Dial Transplant 2009, 24:2021-2023.
122. Hambleton M., Hahn H., Pleger S.T., et al. Pharmacological- and gene therapy-based inhibition of protein kinase C alpha/beta enhances cardiac contractility and attenuates heart failure. Circulation 2006, 114:574-582.
123. Connelly K.A., Kelly D.J., Zhang Y., et al. Inhibition of protein kinase C-beta by ruboxistaurin preserves cardiac function and reduces extracellular matrix production in diabetic cardiomyopathy. Circ Heart Fail 2009, 2:129-137.
124. Tuttle K.R., Bakris G.L., Toto R.D., et al. The effect of ruboxistaurin on nephropathy in type 2 diabetes. Diabetes Care 2005, 28:2686-2690.
125. Gilbert R.E., Kim S.A., Tuttle K.R., et al. Effect of ruboxistaurin on urinary transforming growth factor-beta in patients with diabetic nephropathy and type 2 diabetes. Diabetes Care 2007, 30:995-996.
126. Tuttle K.R., McGill J.B., Haney D.J., et al. Kidney outcomes in long-term studies of ruboxistaurin for diabetic eye disease. Clin J Am Soc Nephrol 2007, 2:631-636.
127. Palaniyandi S.S., Sun L., Ferreira J.C., et al. Protein kinase C in heart failure: a therapeutic target?. Cardiovasc Res 2009, 82:229-239.
128. Goh S.Y., Cooper M.E. Clinical review: the role of advanced glycation end products in progression and complications of diabetes. J Clin Endocrinol Metab 2008, 93:1143-1152.
129. Williams M.E., Tuttle K.R. The next generation of diabetic nephropathy therapies: an update. Adv Chronic Kidney Dis 2005, 12:212-222.
130. Bolton W.K., Cattran D.C., Williams M.E., et al. ACTION I Investigator Group. Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy. Am J Nephrol 2004, 24:32-40.
131. Williams M., Bolton W., Khalifah R., et al. Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. Am J Nephrol 2007, 27:605-614.
132. Kanai Y., Lee W.S., You G., et al. The human kidney low affinity Na+/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose. J Clin Invest 1994, 93:397-404.
133. Wright E.M., Turk E. The sodium/glucose cotransport family SLC5. Pflugers Arch 2004, 447(5):510-518.
134. Freitas H.S., Anhê G.F., Melo K.F., et al. Na(+)-glucose transporter-2 messenger ribonucleic acid expression in kidney of diabetic rats correlates with glycemic levels: involvement of hepatocyte nuclear factor-1α expression and activity. Endocrinology 2008, 149:717-724.
135. Rahmoune H., Thompson P.W., Ward J.M., et al. Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non insulin-dependent diabetes. Diabetes 2005, 54:3427-3434.
136. Nair S., Wilding J.P. Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus. J Clin Endocrinol Metab 2010, 95:34-42.
137. Bristol Myers-Squibb Clinical trials disclosure: clinical trials for metabolic disease Available at:, Accessed January 11, 2010. http://ctr.bms.com/ctd/InitTrialAction.do?linkname=Metabolics&type=pharma&sortby.